AT&T Attracts Huge Bullish Bets From Options Traders Ahead Of Earnings

AT&T Inc. (NYSE: T) shares traded lower on Monday after the stock was downgraded by Citigroup.

AT&T Inc. (NYSE:T) shares traded lower on Monday after the stock was downgraded by Citigroup.

Citigroup analyst Michael Rollins downgraded AT&T from a Buy rating to a Neutral rating and lowered the price target from $22 to $16, citing potential risks related to lead-sheathed cables.

On CNBC’s “Options Action,”  Mike Khouw of Optimize Advisors said AT&T traded at 6x its average daily options volume, with calls outpacing puts by 2.5 to 1 on Monday. AT&T was also the fifth-busiest single stock on Monday.

Don’t forget to check out our premarket coverage here

There were buyers of 63,500 of the July 14-calls at an average price of 12 cents per contract, Khouw said.

Traders risk less than 1% of AT&T’s share price to bet on a bounce in the stock.

AT&T is scheduled to report second-quarter financial results on July 26 before the market opens. Analysts expect the company to report earnings of 60 cents per share on quarterly revenue of $30 billion.

Price Action: AT&T shares fell 6.7% to close at $13.53 on Monday, but added 0.8% in today’s premarket trading session.

Check This Out: Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Coherus And Junshi Biosciences Announce Publication Of Final Overall Survival Results Of JUPITER-02, A Phase 3 Trial Evaluating LOQTORZI As Treatment For Nasopharyngeal Carcinoma, In The Journal Of The American Medical Association

– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1

CHRS